insights_auto
Why is FARON down 2.39%?
Dive Deeperchevron_right
FARON:HEL
Faron Pharmaceuticals Oy
€0.37
arrow_downward
-2.39%(-0.0090) 1D
Oct 26, 5:01:44 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARON...
Open
€0.38
High
€0.38
Low
€0.37
Mkt. cap
67.01M
Avg. vol.
592.04K
Volume
566.02K
52-wk high
€2.24
52-wk low
€0.37
Shares outstanding
202.88M
No. of employees
36
Open
€0.38
High
€0.38
Low
€0.37
Mkt. cap
67.01M
Avg. vol.
592.04K
Volume
566.02K
52-wk high
€2.24
52-wk low
€0.37
Shares outstanding
202.88M
No. of employees
36
News stories
From web sources and news partners
Investing.com
·
37 minutes ago
Dow Jones pulls back to MA cluster near 52,400: Live levels
TradingView
·
48 minutes ago
U.S. stocks advance ahead of key tech earnings, Fed decision
Yahoo Finance UK
·
1 hour ago
US Stock Futures Point Higher as Crude Oil Retreats and Investors Await Fed Meeting: Dow Jones, S&P, Nasdaq, Wall Street
Benzinga
·
16 minutes ago
Nvidia Stock Hits Deepest Discount to S&P 500 Since 2015 - NVIDIA (NASDAQ:NVDA)
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy